Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Radiation boosts immunotherapy in lung cancer? new trial aims to find out

NCT ID NCT07353476

Disease control Sponsor: Shanghai Zhongshan Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at people with stage III non-small cell lung cancer who had chemotherapy plus immunotherapy before surgery, and still had cancer in their lymph nodes after the tumor was removed. Half will get standard immunotherapy alone after surgery, and the other half will get immunotherapy plus radiation to the lymph nodes. The goal is to see if the combination helps keep the cancer from coming back longer.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
radiation therapy and an anti-PD-1 immunotherapy drug
What this could lead to
If it works, this could point toward a more effective treatment plan for lung cancer patients who still have cancer in their lymph nodes after surgery and chemotherapy.
What could go wrong
This is a small, early-phase study with only 38 participants, so results may not apply to everyone. Adding radiation also raises risks of side effects like lung inflammation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 38 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Jun 2032

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18-75 years, male or female. * Histologically confirmed NSCLC (adenocarcinoma, squamous cell carcinoma, or other NSCLC subtypes). * Clinical stage IIIA/IIIB at initial diagnosis, deemed suitable for neoadjuvant chemoimmunotherapy followed by surgery according to MDT. * Completed 2-4 cycles of platinum-based doublet chemotherapy plus PD-1 inhibitor as neoadjuvant therapy. * Underwent R0 resection (anatomical lobectomy or pneumonectomy with mediastinal lymph node dissection). * Postoperative pathological stage ypT\_anyN⁺M0 (residual nodal metastasis in mediastinal or hilar lymph nodes). * ECOG performance status 0-1. * Adequate hematologic, hepatic, and renal function per protocol-defined lab thresholds. * Able to start postoperative radiotherapy and/or PD-1 maintenance within 4-10 weeks after surgery (or after recovery from postoperative complications, as clinically appropriate). * Signed written informed consent. Exclusion Criteria: * Positive surgical margins (R1 or R2) or incomplete resection. * Prior thoracic radiotherapy that would overlap with planned treatment fields. * Active, uncontrolled infection or unresolved ≥ Grade 2 immune-related adverse events. * History of severe autoimmune disease requiring systemic immunosuppression. * Uncontrolled interstitial lung disease or significant pulmonary fibrosis. * Symptomatic or untreated central nervous system metastases at enrollment. * Any condition that, in the investigator's judgment, would compromise patient safety or protocol compliance.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSCLC (advanced non-small cell lung cancer) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NSCLC (advanced non-small cell lung cancer) Post-surgical

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.